{"data":[{"dar_ID":11386,"expiration_date":"2027-03-31 17:02:38","approval_date":"2026-03-31 17:02:38","initial_approval_date":"2025-01-06 18:33:03","project_name":"Elucidating sex-specific risk for Alzheimer's disease through state-of-the-art genetics and multi-omics","status_name":"Approved","first_name":"Michael","last_name":"Belloy","institution":"Washington University in St Louis","dataset_accessions":["NG00175"],"publications":["41588232","41437896","41404291","41282793"],"dar_publications":["41588232","41437896","41404291","41282793"],"researchSTMT":"•\tObjectives: In this project, we seek to holistically investigate the genetic and molecular drivers of sex dimorphism in Alzheimer’s disease across ancestries. \n•\tStudy design: This study integrates large-scale population genetics with multi-omics and endophenotype analyses. We are integrating all data available from ADGC and ADSP, together with other data from AMP-AD and biobanks such as UKB, FinnGen, and MVP to conduct large-scale multi-ancestry GWAS, rare-variant gene aggregation analyses, QTL studies, PWAS, TWAS, etc. We also particularly focus on X chromosome association studies. The study design also interrogates interactions with ancestry, hormone exposures, and with APOE*4, as well as comparisons to non-stratified GWAS/XWAS of Alzheimer’s disease. Further, we will also employ genetic correlation analyses, mendelian randomization, colocalization, and pleiotropy analyses, to interrogate overlap with other complex traits to better understand the mechanisms underlying sex dimorphism in Alzheimer’s disease. \n•\tAnalysis plan, including the phenotypic characteristics that will be evaluated in association with genetic variants: Our phenotypes will include Alzheimer’s disease risk, conversion risk, various endophenotypes (including amyloid/tau biomarkers, brain imaging metrics, etc.) as well as molecular traits. As noted above, we will conduct large-scale multi-ancestry GWAS, XWAS, rare-variant gene aggregation analyses, QTL studies, PWAS, TWAS, etc. Specific aims include interrogating these question and analyses on (1) the autosomes, (2) the X chromosome, and (3) leveraging sex stratified QTL studies to drive discovery of risk genes.\n","ntResearchSTMT":"Alzheimer’s disease (AD) manifests itself differently across men and women, but the genetic and molecular factors that drive this remain elusive. AD is the most common cause of dementia and till today remains largely untreatable. It is thus crucial to study the genetics of AD in a sex-specific manner, as this will help the field gain important insights into disease pathophysiology, identify novel sex-specific risk factors relevant to personalized genetic medicine, and uncover potential new AD drug targets that may benefit both sexes. This project uses large-scale genomics and multi-omics to elucidate novel sex agnostic and sex-specific AD risk genes. We will interrogate sex dimorphism for AD risk on the autosomes and the sex chromosomes. We similarly interrogate sex dimorphism in the genetic regulation of gene expression and protein levels, which we will integrate with genetic risk for Alzheimer’s disease to further discovery risk genes. Throughout, we will also interrogate how sex-specific risk for AD interactions with hormone exposures, ancestry, and the APOE*4 risk allele."},{"dar_ID":10013,"expiration_date":"2027-06-25 21:11:43","approval_date":"2026-06-25 21:11:43","initial_approval_date":"2018-10-29 14:09:35","project_name":"ADSP Data Analysis","status_name":"Approved","first_name":"Lindsay","last_name":"Farrer","institution":"Boston University","dataset_accessions":["NG00175"],"publications":["40407102","40528303","41428483","41040715"],"dar_publications":["40407102","40528303","41428483","41040715","39428839","39428694","39444005","38746629","38418088","38263370","36809323","37051669","37260021","37578203","37930705","35210353","36411364","36539198","35258170","34152079","33804025","31180460","30924900","30108311","30503768"],"researchSTMT":"As part of the Consortium for Alzheimers Sequence Analysis (CASA: NIA grant UF1-AG047133), we  plan to analyze whole exome and whole genome sequence data generated from subjects with Alzheimer's disease (AD) and elderly normal controls. These data will be generated by the National Human Genome Institute Large-Scale Sequence Program. The goal of the planned analyses is to identify genes that have alleles that protect against or increase susceptibility to AD. We will evaluate variants detected in the sequence data for association with AD to identify protective and susceptibility alleles using the whole exome case-control data. We will also evaluate sequence data from multiplex AD families to identify variants associated with AD risk and protection, and evaluate variant co-segregation with AD. The family data will be whole genome data. The family-based data will be used to inform the cases control analysis and visa versa. We also will focus on structural variants (insertion-deletions, copy number variants, and chromosomal rearrangements). Evaluation of structural variants will involve both whole genome and whole exome data. Structural variants will be analyzed with single nucelotide variants detected and analyzed in the case-control and family-based data.","ntResearchSTMT":"We are attempting to identify all the inherited elements that contribute to Alzheimer's disease risk. To do this we will analyze DNA sequence data from subjects with Alzheimer's disease and elderly subjects who are cognitively normal. The sequence data from these 2 groups will be compared to identify differences that contribute to the risk of developing Alzheimer's disease of that protect against Alzheimer's disease. These DNA differences can be at a single site in the genetic code, or can span multiple sites, changing the copy number of DNA sequences. Both types of genetic variants will be examined.   "},{"dar_ID":12038,"expiration_date":"2027-02-10 12:59:57","approval_date":"2026-02-10 12:59:57","initial_approval_date":"2026-02-10 12:59:57","project_name":"GADIR","status_name":"Approved","first_name":"Victoria","last_name":"Fernandez","institution":"ACE Alzheimer Center","dataset_accessions":["NG00175"],"publications":[],"dar_publications":[],"researchSTMT":"The objective of this study is to contribute to our understanding of neurodegenerative diseases by examining the genetic contributors of major dementia neuropathological hallmarks (amyloid-β deposition, tau pathology, TDP-43, hippocampal sclerosis, Lewy body pathology, and cerebrovascular disease, among others. We will generate the largest Iberian database(N=3500) of neuropathologically curated brains (Aim 1) with a subset of those (N≈350) undergoing deep digital phenotyping (Aim 3). We will generate an associated genetic map (Aim 2) order to elucidate how common and rare genetic variants contribute to specific pathologies. We additionally aim to determine how polygenic risk scores (PRS) and pathway-specific PRS correspond to single and mixed neuropathological profiles, and to clarify the genetic architecture driving co-pathologies that frequently complicate clinical diagnosis. Eventually, we will replicate and fine-map our findings (Aim 4) leveraging available datasets at NIAGADS and other public repositories.\n\nOur analysis plan includes genome-wide association testing of ordinal, binary, and quantitative neuropathological traits; rare-variant burden analyses for coding and non-coding regions; PRS and pathway-PRS modeling across multiple dementia-related diseases; unsupervised clustering to identify variant sets defining specific endophenotypes; and pathway and network analyses to interpret significant signals. Colocalization and functional annotation approaches will integrate genomic findings with transcriptomic and proteomic resources.\n\nData obtained from NIAGADS will be used to strengthen replication, broaden meta-analytic power, validate associations across independent neuropathology cohorts, and support functional interpretation using available genetic, expression, and multi-omic datasets. All analyses will use de-identified data in compliance with ethical and data-sharing standards.","ntResearchSTMT":"Dementia is an immensely challenging and prevalent condition, deeply impacting the lives of over 55 million individuals worldwide. While Alzheimer's disease stands as the most commonly recognized form of dementia, there exist other conditions that present comparable symptoms but distinct underlying pathological characteristics. To provide more effective support to patients and their families, we need to better understand the genetic causes associated to each of these brain pathologies, and to develop advanced tools for early classification and diagnosis. This grant proposal aims to tackle these challenges by establishing the largest Iberian (Spanish and Portuguese) database of dementia neuropathological cases, marked by a modernized and standardized neuropathological classification alongside comprehensive genomic data. Our goal is to delve further into the genetic architecture underpinning these pathological features and to refine existing risk assessment tools for more accurate diagnoses."},{"dar_ID":10008,"expiration_date":"2027-07-08 15:00:01","approval_date":"2026-07-08 15:00:01","initial_approval_date":"2018-09-17 16:19:09","project_name":"Study of Alzheimer's disease and other dementias (e.g. frontotemporal dementia) and related phenotypes","status_name":"Approved","first_name":"Alison","last_name":"Goate","institution":"Icahn School of Medicine at Mount Sinai","dataset_accessions":["NG00175"],"publications":["40111762"],"dar_publications":["40111762","41040731","40676597","40533518","40470240","40084664","40033057","39937857","38448474","39251599","36907103","36824752","35005195","35379992","34978149","34874463","34757660","34719765","35750033","33712570","34470617","34417470","34386572","34301914","34041846","33589841"],"researchSTMT":"Alzheimer's disease (AD) is the most common form of dementia but has no effective prevention or treatment. Developing a comprehensive picture of the genetic architecture of AD including a network level functional assessment of risk/resilience genes is essential to develop novel therapeutic targets. The overarching goals of this study are to use genetic and genomic approaches to: 1) identify genes and variants that are involved in the development of AD and related disorders; 2) identify functional networks enriched for AD or related disorder risk and protective loci; 3) determine how cellular function and physiology is impacted by these genetic factors in disease-relevant cell types and animal models. This study will use publicly available whole genome/exome sequence data generated by the Alzheimer’s Disease Sequencing Project (ADSP) and genome-wide association study (GWAS) data from the International Genomics of Alzheimer’s Project (IGAP) and others. We will apply a suite of case-control and family approaches to investigate genetic association with dichotomous and continuous disease traits. This study will not only further our understanding of the genetic architecture of AD but also provide key information regarding the molecular mechanisms, setting the stage for novel therapeutic development.\n","ntResearchSTMT":"Alzheimer’s disease (AD) is the only disease among the top ten killers in the U.S. without a disease modifying therapy. Genetic studies provide a powerful means to identify genes and pathways that are causally linked to disease etiology. We propose to use genomic and functional approaches to identify genes that alter the risk of AD and investigate how these genes disrupt cellular pathways leading to disease.\n"},{"dar_ID":12573,"expiration_date":"2027-10-30 19:58:24","approval_date":"2026-10-30 19:58:24","initial_approval_date":"2026-10-30 19:58:24","project_name":"ADAPTT","status_name":"Approved","first_name":"Jonathan","last_name":"Haines","institution":"Case Western Reserve University","dataset_accessions":["NG00175"],"publications":[],"dar_publications":[],"researchSTMT":"Objectives: The overall goal of the planned analyses for ADAPTT is to better characterize the known genetic loci that are associated with AD/ADRD to identify the most probable functional elements responsible for the association. Most of these known associations have not been assigned to specific genes or functional variants.\nWe plan to analyze DNA variation from SNP array, whole exome and whole genome sequence data generated from participants that span the spectrum of dementia (with a focus on Alzheimer disease (AD) but also including MCI and related dementias [ADRD]) and participants without dementia (typically considered “controls”). \n\nStudy Design: We will evaluate these known loci, including the many genes underlying these associations, by integrating available genetic data, genomic data, in silico annotations, and multi-omic data using multiple different computational approaches. Our approaches will be sensitive to the different study designs of the contributing datasets (e.g. cohort studies, case-control studies, family-based studies). We will also examine a small number of these loci, prioritized by our analyses, using molecular genomic methods to better characterize the molecular mechanisms underlying the associations.\n\nCollaboration: This is a collaboration with Drs. Martin, Pericak-Vance, and Vance at the University of Miami.\n\n","ntResearchSTMT":"We are attempting to identify the inherited elements that contribute to Alzheimer disease risk. To do this we will analyze DNA sequence data from participants with Alzheimer disease and related dementias along with subjects who are cognitively normal. There are many known regions of the human genome that are associated with AD/ADRD risk, but the actual DNA sequence variations that are responsible for those associations remain unknown. Our goal is to use statistical and computer methods to identify the underlying responsible variations. For a small number of these, we will directly examine the biological mechanisms that help explain how those variations impact AD/ADRD.\n\n"},{"dar_ID":10121,"expiration_date":"2027-03-16 17:31:51","approval_date":"2026-03-16 17:31:51","initial_approval_date":"2019-11-08 15:07:35","project_name":"Genetic Drivers of Resilience to Alzheimer's Disease","status_name":"Approved","first_name":"Timothy","last_name":"Hohman","institution":"Vanderbilt University Medical Center","dataset_accessions":["NG00175"],"publications":[],"dar_publications":["37985223","37984853","38760857","36993746","38967222","33687445","33830999","33926499","33455611","31332262","34479171","33568538","34852950","34890163"],"researchSTMT":"“Asymptomatic” Alzheimer’s disease (AD) is a phenomenon in which 30% of individuals over age 65 meet criteria for autopsy-confirmed pathological AD (beta-amyloid plaques and tau aggregation) but do not clinically manifest cognitive impairment.1-3 The resilience that underlies asymptomatic AD is marked by both protection from neurodegeneration (brain resilience)4 and preserved cognition (cognitive resilience). \n\nOur central hypothesis is that\ngenetic effects allow a subset of individuals to endure extensive AD neuropathology without marked brain atrophy or cognitive impairment. We are uniquely positioned to identify resilience genes by leveraging the Resilience from Alzheimer’s Disease (RAD) database, a local resource in which we\nhave harmonized a validated quantitative phenotype of resilience across 8 large AD cohort studies.\n\nOur strong interdisciplinary team represents international leaders in genetics, neuroscience, neuropsychology, neuropathology, and psychometrics who will leverage the infrastructure and rich  resources of the AD Genetics Consortium, IGAP, ADSP, and our recently established and harmonzed continuous metric of resilience to fulfill the following aims:\n\nAim 1. Identify and replicate common genetic variants that predict cognitive resilience (preserved cognition) and brain resilience (protection from brain\natrophy) in the presence of AD pathology. We hypothesize that common genetic variation will explain variance in resilience above and beyond known\npredictors like education. Replication analyses will leverage age of onset data from IGAP to demonstrate that resilience loci predict a later age of AD onset.\n\nAim 2. Identify and replicate rare and low-frequency genetic variants that predict cognitive and brain resilience. Rare and low-frequency variants with large effects have been identified in AD case/control studies, providing new insight into the genetic architecture of AD.\n\nAim 3: Identify sex-specific genetic drivers of cognitive and brain resilience to AD pathology. Our preliminary results highlight sex differences in the downstream consequences of AD neuropathology, including sex-specific genetic markers of resilience.","ntResearchSTMT":"As the population ages, late-onset Alzheimer’s disease (AD) is becoming an increasingly important public health issue. Clinical trials targeted a reducing AD progression have demonstrated that patients continue to decline despite therapeutic intervention. Thus, there is a pressing need for new treatments aimed at novel therapeutic targets. A shift in focus from risk to resilience has tremendous potential to have a major public health impact by highlighting mechanisms that naturally counteract the damaging effects of AD neuropathology. The goal of the present project is to characterize genetic factors that protect the brain from the downstream consequences of AD neuropathology. We will identify both rare and common genetic\nvariants using a robust metric of resilience developed and validated by our research team. The identification of such genetic effects will provide novel targets for therapeutic intervention in AD."},{"dar_ID":11542,"expiration_date":"2027-03-31 19:56:47","approval_date":"2026-03-31 19:56:47","initial_approval_date":"2025-01-07 19:16:05","project_name":"Genetics of Alzheimer's Disease and Endophenotypes","status_name":"Approved","first_name":"M. Ilyas","last_name":"Kamboh","institution":"University of Pittsburgh","dataset_accessions":["NG00175"],"publications":[],"dar_publications":[],"researchSTMT":"Objectives: \nWe are requesting access to the NIAGADS datasets to augment our ongoing studies on the genetics of Alzheimer’s disease (AD) and AD-related endophenotypes being carried out by Kamboh and his group since 1995.  We are doing GWAS using array genotypes, whole-exome sequencing and whole-genome sequencing on datasets derived from University of Pittsburgh ADRC and ancillary population-based longitudinal studies on dementia and biomarkers. Different available phenotypes include AD and non-AD dementia, age-at-set, disease progression and survival, neuroimaging, cognitive decline, plasma biomarkers for the core ATN and non-ATN pathologies. We also plan to expand on gene-gene interaction and sex-stratified analyses which require the actual genotype data. The NIAGADS datasets will be used for replication and meta-analysis, and for gene-gene interaction and sex-stratified analyses. \nStudy Design: \nA case-control design will incorporate a diverse cohort of individuals with AD and age-matched controls. For quantitative traits (neuroimaging and plasma biomarkers, cognitive performance measures, indicators of disease progression), linear regression analyses will be performed to identify genetic loci. To ensure the findings are robust and inclusive, participants from diverse demographic backgrounds will be included, enabling the exploration of potential genetic variations across populations.\nAnalysis Plan: \nWe will conduct GWAS and targeted analyses on candidate genes on different AD and AD-related phenotypes. Primary phenotypic variables include AD disease status, age-at-onset, last age for controls, APOE genotype, cognitive decline trajectories, sex, and race. Analyses will evaluate the influence of specific genetic variants on disease risk, cognitive performance, and biomarker levels, considering both individual and interactive effects of the APOE genotype. Results will be adjusted for potential confounders, such as demographic factors, to ensure valid associations. Detail analytical methods are described in our published papers for case-control (PMID: 32651314;35694926), quantitative traits (PMID: 30361487;37666928), and cognitive decline (PMID: 37089073; 30954325).\n","ntResearchSTMT":"Our research group at the University of Pittsburgh (Pitt), has been working on the genetics of Alzheimer’s disease (AD) and AD-related endophenotypes for almost three decades, on data derived largely from the University of Pittsburgh  Alzheimer’s Disease Research Center and ancillary dementia studies. We are requesting access to the NIAGADS genotype and phenotype datasets to augment our sample size to increase power to detect novel genetic associations with AD and related endophenotypes."},{"dar_ID":12385,"expiration_date":"2027-07-20 18:24:08","approval_date":"2026-07-20 18:24:08","initial_approval_date":"2026-07-20 18:24:08","project_name":"Discovery of APOE-Interacting Genes Through Trans-Ancestry and Sex-Stratified Analysis to Elucidate Alzheimer's Disease Risk Mechanisms and Stratify ARIA Risk Using Proxy Outcomes","status_name":"Approved","first_name":"Jong Hun","last_name":"Kim","institution":"KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION","dataset_accessions":["NG00175"],"publications":[],"dar_publications":[],"researchSTMT":"Objectives: This project identifies ancestry- and sex-specific APOE ε4 modifier genes—variants that amplify or attenuate APOE ε4’s effect on AD risk and ARIA susceptibility from anti-amyloid immunotherapy. Aim 1: Trans-ancestry sex-stratified GWIS to construct an APOE-Wide Epistasis Map. Aim 2: Mechanistic validation via eQTL/pQTL colocalization and epistasis network. Aim 3: Explainable AI (XAI) integrating modifier SNPs, multi-omics subtypes, and ARIA proxy outcomes to stratify pre-treatment ARIA risk.\nStudy Design: Multi-cohort secondary analysis using NIAGADS-controlled ADSP data exclusively. Individual-level data from all 15 ADC cohorts (NG00022–NG00151) and multi-ancestry ADSP WGS (NG00067, NG00166) span European, African American, Hispanic/Latino, and South/East Asian ancestries. Functional datasets (eQTL/pQTL: NG00102, NG00118, NG00120, NG00130) support Aim 2; imaging and neuropathology datasets (NG00103, NG00147, NG00175) enable Aim 3 ARIA proxy development. No prospective recruitment.\nMulti-dataset rationale: GWIS requires 4–8× more samples than standard GWAS (Gauderman 2002); no single cohort is independently powered—all 15 ADC cohorts must be pooled. Trans-ancestry GWIS requires ancestry-matched datasets (NG00100/African, NG00106/South Asian, NG00141/Hispanic) because population-specific LD cannot be imputed from summary statistics. Functional datasets (eQTL, pQTL, methylation) are non-redundant—each covers a distinct regulatory layer for Aim 2. All datasets are AD-specific; non-AD neurodegeneration data are excluded.\nAnalysis Plan: Phenotypes: AD case/control (primary); APOE ε4 × SNP interaction; lobar microbleed count (ARIA-H proxy); SVD score (WMH, lacunar infarcts, perivascular spaces); longitudinal cognitive decline. Covariates: age, sex, top 20 ancestry PCs, stratum. Methods: logistic GWIS; trans-ancestry meta-analysis (METAL/MR-MEGA); sex-stratified/X-chromosome analyses; eQTL/pQTL colocalization (COLOC2/SMR); XGBoost XAI with 5-fold CV and SHAP.\n","ntResearchSTMT":"Alzheimer’s disease affects tens of millions worldwide. Lecanemab, approved in 2024, slows Alzheimer’s progression by removing amyloid plaques—but causes dangerous brain side effects (ARIA: Amyloid-Related Imaging Abnormalities) especially in APOE ε4 carriers, who also most need treatment. Currently, doctors cannot predict which APOE ε4 carriers will benefit versus be harmed.\n\nOur research identifies modifier genes controlling how dangerous APOE ε4 is. We leverage the ADSP’s diverse dataset spanning 15+ cohorts across European, African American, Hispanic/Latino, and Asian ancestries—a scale statistically necessary because detecting gene–gene interactions requires 4–8× more samples than standard genetic studies. Population-specific patterns allow high-confidence modifier identification. MRI-based brain bleeds and vascular markers serve as validated ARIA surrogates available at scale.\n\nThe result is an explainable AI tool that predicts—before treatment begins—which APOE ε4 patients face high ARIA risk and which will benefit from lecanemab, enabling precision Alzheimer’s therapy.\n"},{"dar_ID":10141,"expiration_date":"2027-07-29 17:05:33","approval_date":"2026-07-29 17:05:33","initial_approval_date":"2019-12-18 15:47:57","project_name":"Powerful and novel statistical methods to detect genetic variants associated with or putative causal to Alzheimer’s disease","status_name":"Approved","first_name":"Wei","last_name":"Pan","institution":"University of Minnesota","dataset_accessions":["NG00175"],"publications":["40209152","41537459"],"dar_publications":["40209152","41537459","36179104"],"researchSTMT":"We have been developing more powerful statistical methods to detect common variant (CV)- or rare variant (RV)-complex trait associations and/or putative causal relationships for GWAS and DNA sequencing data. Here we propose applying our new methods, along with other suitable existing methods, to the existing ADSP sequencing data and other AD GWAS data provided by NIA, hence requesting approval for accessing the ADSP sequencing and other related GWAS/genetic data. We have the following two specific Aims:\nAim1. Association testing under genetic heterogeneity: For complex traits, genetic heterogeneity, especially of RVs, is ubiquitous as well acknowledged in the literature, however there is barely any existing methodology to explicitly account for genetic heterogeneity in association analysis of RVs based on a single sample/cohort. We propose using secondary and other omic data, such as transcriptomic or metabolomic data, to stratify the given sample, then apply a weighted test to the resulting strata, explicitly accounting for genetic heterogeneity that causal RVs may be different (with varying effect sizes) across unknown and hidden subpopulations. Some preliminary analyses have conﬁrmed power gains of the proposed approach over the standard analysis. \nAim 2. Meta analysis of RV tests: Although it has been well appreciated that it is necessary to account for varying association effect sizes and directions in meta analysis of RVs for multi-ethnic cohorts, existing tests are not highly adaptive to varying association patterns across the cohorts and across the RVs, leading to power loss. We propose a highly adaptive test based on a family of SPU tests, which cover many existing meta-analysis tests as special cases. Our preliminary results demonstrated possibly substantial power gains.\nAim 3. Inferring (putative) causal genes/proteins/metabolites for AD. We will apply TWA/PWAS/MWAS/xWAS methods to ADSP, AD GWAS and other omic data to identify (putative) causal genes, proteins, metabolites and other molecular traits for AD. These methods may be based on standard linear models or emerging ML/AI methods. \n","ntResearchSTMT":"We propose applying our newly developed statistical and computational methods, along with other suitable existing methods, to the existing ADSP sequencing data, other AD GWAS data and other omic data to detect common or rare genetic variants and other molecular traits, such as genes/proteins/metabolites, associated with and/pr (putative) causal to Alzheimer’s disease (AD). The novelty and power of our new methods are in three aspects: first, we consider and account for possible genetic heterogeneity with several subcategories of AD; second, we apply powerful meta-analysis methods to combine the association analyses across multiple subcategories of AD; third, we will develop and apply standard linear model- and emerging ML/AI-based causal inference methods to infer causal genes, proteins, metabolites and other traits for AD. In addition, our proposed analyses of the existing large amount of ADSP sequencing data and other AD GWAS data with our developed new methods are novel, powerful and cost-effective."},{"dar_ID":12317,"expiration_date":"2027-06-01 20:53:59","approval_date":"2026-06-01 20:53:59","initial_approval_date":"2026-06-01 20:53:59","project_name":"Genome-wide search for pleiotropy in ischemic stroke, normal pressure hydrocephalus, and neuropathology endophenotypes linked to Alzheimer’s disease","status_name":"Approved","first_name":"Young Ho","last_name":"Park","institution":"Seoul National University Bundang Hospital","dataset_accessions":["NG00175"],"publications":[],"dar_publications":[],"researchSTMT":"- Objectives of the proposed research: Accumulating evidence indicates that ischemic stroke (IS) and normal pressure hydrocephalus (NPH) share common risk factors and critical mechanisms with Alzheimer’s disease (AD). This study aims to identify pleiotropy between (1) IS and AD-associated neuropathology endophenotypes (NPEs) and (2) NPH and AD-associated NPEs. Based on the identified pleiotropic variants or loci, we will also investigate shared pathways underlying biological mechanisms of IS, NPH, and AD.\n\n- Study design: We will conduct genome-wide pleiotropy analyses using summary statistics obtained from previous genome-wide association studies (GWAS) for IS, NPH, and AD-associated NPEs. Along with GWAS summary statistics for NPEs (Shade et al., 2024, Nat Genet), we will use GWAS summary statistics for IS (Malik et al., 2018, Nat Genet) and NPH (Rasanen et al., 2024, Neurology), generated in individuals of European ancestry.\n\n- Analysis plan: Two separate genome-wide pleiotropy analyses will be conducted: (1) pleiotropy GWAS for IS and AD-associated NPEs and (2) pleiotropy GWAS for NPH and AD-associated NPEs. We will evaluate pleiotropy for variants with minor allele frequency (MAF) > 0.01 and Z-scores < 80 using the R package PLACO, which examines the composite null hypothesis that a given variant is associated with a maximum of one trait, such that rejecting this hypothesis implies that the variant influences both traits and is thus pleiotropic. For top-ranked loci containing genome-wide significant pleiotropic variants, we will differentiate horizontal pleiotropy from mediated pleiotropy by conducting Bayesian colocalization analysis using the R package COLOC. We also plan to conduct pathway enrichment analyses for top-ranked pleiotropic variants to identify pathways underlying biological mechanisms shared by IS, NPH, and AD.\n\n- Planned collaboration: There are no planned collaborations with researchers at other institutions for this study.","ntResearchSTMT":"Accumulating evidence indicates that ischemic stroke (IS) and normal pressure hydrocephalus (NPH) are known to share common risk factors and critical mechanisms with Alzheimer’s disease (AD). Although large-scale genome-wide association studies (GWAS) have identified many variants or loci associated solely with IS, NPH, and AD, only a few studies have investigated shared genetic factors or pathways underlying their biological mechanisms. This study aims to identify variants or loci that influence AD-associated neuropathology endophenotypes (NPEs) and IS or AD-associated NPEs and NPH simultaneously. Using GWAS summary statistics for each neurodegenerative disease, we will conduct genome-wide pleiotropy analyses, differentiate horizontal pleiotropy (direct genetic effect on AD or through mechanisms that bypass IS or NPH) from mediated pleiotropy (genetic effect on AD through IS or NPH), and investigate biological pathways implicated in shared mechanisms of IS, NPH, and AD. Our findings may provide insight into the genetic basis and underlying mechanisms shared by IS, NPH, and AD."},{"dar_ID":10085,"expiration_date":"2027-03-13 19:47:00","approval_date":"2026-10-21 19:47:42","initial_approval_date":"2020-10-14 14:30:45","project_name":"Therapeutic target discovery in ADSP data via comprehensive whole-genome analysis incorporating ethnic diversity and systems approaches","status_name":"Approved","first_name":"Sudha","last_name":"Seshadri","institution":"Glenn Biggs Institute for Alzheimer&#39;s and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX","dataset_accessions":["NG00175"],"publications":["41560352","41720779","42024100"],"dar_publications":["41560352","41720779","42024100","38511601","39428839","40084664","37923804","37322115","37333771"],"researchSTMT":"Objective: Utilize ADSP data sets to identify genes & specific genetic variants that confer risk for or protection from Alzheimer disease.\nAim 1: Using combined WGS/WES across the ADSP Discovery, Disc-Ext, and FUS Phases, including single nucleotide variants, small insertion/deletions, and structural variants. We will:\nAim 1a. Perform whole genome single variant and rare variant case/control association analyses of AD using ADSP and other available data;\nAim 1b. Target protective variant identification via association analysis using selected controls within the ADSP data and performing meta analysis across association results based on selected controls from non-ADSP data sets.\nAim 1c. Perform endophenotype analyses including cognitive function measures, hippocampal volume and circulation beta-amyloid ADSP data in subjects for which these measures are available. Meta analysis will be conducted across ADSP and non-ADSP analysis results.\nAim 2: To leverage ethnically-diverse and admixed populations to identify AD variants we will:\nAim 2a. Estimate and account for global and local ancestry in all analyses;\nAim 2b. Perform admixture mapping in samples of admixed ancestry; and\nAim 2c. Perform ethnicity-specific and trans-ethnic meta-analyses.\nAim 3: To identify putative therapeutic targets through functional characterization of genes and networks via bioinformatics, integrative omics analyses. We will:\nAim 3a. Annotate variants with their functional consequences using bioinformatic tools and publicly available “omics” data.\nAim 3b. Prioritize results, group variants with shared function, and identify key genes functionally related to AD via weighted association analyses and network approaches.\nAnalyses will be performed in coordination with the following PIs. Coordination will involve sharing expertise, analysis plans or analysis results. No individual level data will be shared across institutions. Philip De Jager, Columbia University; Eric Boerwinkle & Myriam Fornage, UT Health Science Center at Houston; Sudha Seshadri, UT Health Science Center at San Antonio; Ellen Wijsman, University of Washington; William Salerno, Baylor College of Medicine.","ntResearchSTMT":"This proposal seeks to analyze existing genetic sequencing data generated as part of the Alzheimer’s Disease Sequencing Project (ADSP) including the ADSP Follow-up Study (FUS) with the goal of identifying genes and specific changes within those genes that either confer risk for Alzheimer’s disease or provide protection from Alzheimer’s disease. Analytic challenges include analysis of whole genome sequencing data, appropriately accounting for population structure across European ancestry, Hispanic, and African American participants, and interpreting results in the context of other genomic data available."},{"dar_ID":11491,"expiration_date":"2027-01-21 15:15:35","approval_date":"2026-01-21 15:15:35","initial_approval_date":"2026-01-21 15:15:35","project_name":"Identifying Alzheimer's Disease Genetic Risk Factors By Integrated Genomic and Proteomic Analysis","status_name":"Approved","first_name":"Thomas","last_name":"Wingo","institution":"University of California Davis","dataset_accessions":["NG00175"],"publications":[],"dar_publications":[],"researchSTMT":"We aim to uncover new genetic risk variants for Alzheimer’s disease (AD), AD-related dementia (ADRD), and behavioral and psychiatric symptoms (BPS) associated with AD/ADRD.  We expect to use whole-genome sequencing (WGS), whole-genome genotyping (WGG), and whole-exome sequencing (WES) data. Additionally, we will use the results of brain proteomic analysis to nominate genes and pathways for AD, ADRD, and dementia BPS.  We plan to publish our findings to share them with the scientific community.\n\nOutcomes that will be tested include: (1) clinical disease status, (2) pathologic characterization (e.g., measures of beta-amyloid, tau, etc.), (3) cognitive decline, (4) BPSD, and (5) outcomes related to AD/ADRD severity. For sequencing data, we will extract raw sequencing reads from CRAM/BAM (or equivalent encrypted files) and re-map those to hg38 build of the human genome using PEMapper. Bascalling will be performed using PECaller using default settings. Variant annotation will use Bystro and quality control will follow approaches to assess completeness and account for ancestry as is customary in our lab. For rare variants, we will a variety of kernel-based approaches and for common variants, use standard statistical modeling. For all analyses, we plan to control for population structure deriving principal components from the underlying sequencing or genotyping data.\n","ntResearchSTMT":"Our aim is to identify genetic variants that are associated with Alzheimer's Disease (AD) to uncover new genetic associations. We will examine the role of important risk factors for AD (e.g., age and sex) in our analyses. Separately, we will perform integration of genetic findings for AD with information about how genetic variants influence or are associated with gene expression in the brain, cerebrospinal fluid, or blood to uncover new pathways of disease. Our overarching aim is to use genetic discoveries to identify mechanisms of AD pathogenesis to help nominate new treatment targets."},{"dar_ID":11584,"expiration_date":"2027-06-01 19:42:46","approval_date":"2026-06-01 19:42:46","initial_approval_date":"2025-03-27 20:04:42","project_name":"AIM-AI: an Actionable, Integrated and Multiscale genetic map of Alzheimer's disease via deep learning","status_name":"Approved","first_name":"Zhongming","last_name":"Zhao","institution":"University of Texas Health Science Center at Houston","dataset_accessions":["NG00175"],"publications":[],"dar_publications":[],"researchSTMT":"Objectives: The objective of our study is to advance our understanding of the genetic basis of Alzheimer’s Disease (AD) through the analysis of comprehensive genomic datasets such as Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), single-nuclei RNA sequencing, and Genome-Wide Association Studies (GWAS), as well as the related phenotype. We aim to identify genetic variants that are integral to the development and progression of AD. \n\nStudy Design: Our approach involves a detailed multi-omics analysis focusing on both coding and non-coding regions within these datasets. We will develop new analytical variables from existing data, ensuring that our research adheres to the established data use limitations and contributes meaningfully to the field of genetic research in AD. \n\nAnalysis Plan: The plan centers on investigating the correlation between genetic variants and AD, exploring how these variants influence the disease at a genetic level. We will employ cutting-edge computational methods to analyze interactions between these genetic markers and their potential role in AD pathogenesis. The integration of data from multiple sources will be carefully executed to maintain compliance with data use agreements, emphasizing the scientific exploration of AD.\n","ntResearchSTMT":"Our research is dedicated to unraveling the genetic components of Alzheimer’s Disease. By analyzing genetic sequences and variations through various genomic datasets, we seek to deepen the scientific understanding of how these genetic elements contribute to AD. The outcomes of this study will be shared with the public, enhancing general knowledge of Alzheimer’s Disease and supporting the global research community in its ongoing efforts to decode this complex condition."}]}